

Clinical Cancer Research

Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma

David S. Hong, Kathleen Moore, Manish Patel, et al.

Clin Cancer Res 2018;24:3263-3272. Published OnlineFirst April 11, 2018.

Updated version Access the most recent version of this article at:
[doi:10.1158/1078-0432.CCR-17-3347](https://doi.org/10.1158/1078-0432.CCR-17-3347)

Supplementary Material Access the most recent supplemental material at:
<http://clincancerres.aacrjournals.org/content/suppl/2018/04/11/1078-0432.CCR-17-3347.DC1>

Cited articles This article cites 37 articles, 9 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/24/14/3263.full#ref-list-1>

Citing articles This article has been cited by 2 HighWire-hosted articles. Access the articles at:
<http://clincancerres.aacrjournals.org/content/24/14/3263.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/24/14/3263>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.